Observational studyBMC infectious diseases2026
Emerging predominance of Plasmodium vivax and its contribution to severe malaria in Central Ethiopia: a mixed retrospective-prospective study from two tertiary hospitals.
Observational study in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMalaria remains a major public health challenge in Ethiopia. While Plasmodium falciparum has historically been associated with severe disease, the clinical importance of Plasmodium vivax is increasingly recognized.
objectiveThis study aimed to determine the prevalence, species distribution, severity, associated factors, and clinical outcomes of malaria among adults attending emergency departments in Central Ethiopia.
methodsA mixed retrospective-prospective observational study was conducted in the adult emergency departments of two tertiary hospitals from October 1 to December 31, 2025. Severe malaria was defined according to the 2014 World Health Organization (WHO) criteria. The association between malaria species and severe malaria was examined using bivariate logistic regression.
resultsAmong 318 laboratory-confirmed malaria cases, P. vivax was the predominant species (49.7%), followed by P. falciparum (38.4%) and mixed infections (11.9%). Severe malaria was diagnosed in 65.7% of patients, with severe anaemia (haemoglobin < 5 g/dL) being the most common severity criterion (33.3%). Severe malaria occurred in 65.2% of patients with P. vivax and 67.2% with P. falciparum. No statistically significant association was found between malaria species and severe malaria. Most patients (62.3%) were discharged from the emergency department, while 27.7% were admitted to medical wards. In-hospital mortality was 4.4%.
conclusionP. vivax was the predominant malaria species among adults presenting to the two tertiary hospitals, and both P. vivax and P. falciparum were associated with substantial severe disease. Severe anaemia was the most common manifestation. Strengthening early diagnosis, prompt treatment, species-specific case management, and appropriate radical cure for P. vivax remains important for malaria control and elimination efforts. CLINICAL TRIAL STATEMENT: This manuscript does not describe a clinical trial.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.